MANE Company Profile and Key Details

NYSE : MANE

Veradermics

$107.88

3.98+3.83%

Open: 2:14 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Veradermics, Incorporated (MANE) stock surged +3.83%, trading at $107.88 on NYSE, up from the previous close of $103.90. The stock opened at $104.00, fluctuating between $102.70 and $110.13 in the recent session.

Stock Snapshot

103.9

Prev. Close

4.44B

Market Cap

102.7

Day Low

-45.33

P/E Ratio

-2.38

EPS (TTM)

N/A

Cash Flow per Share

104

Open

41.18M

Number of Shares

110.13

Day High

N/A

Free Float in %

N/A

Book Value

193.49K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 12, 2026	109.01	112.48	103.17	103.90	560.45K
May 11, 2026	105.00	111.36	104.68	108.13	369.5K
May 08, 2026	107.88	110.79	105.23	106.14	496.3K
May 07, 2026	109.57	112.85	106.48	107.85	592.23K
May 06, 2026	114.80	117.71	107.90	109.77	901.18K
May 05, 2026	104.99	116.00	104.65	114.80	1.07M
May 04, 2026	100.95	105.38	99.50	105.26	786.99K
Apr 30, 2026	107.36	114.50	97.51	99.00	1.77M
Apr 29, 2026	105.15	107.92	98.02	106.55	713.54K
Apr 28, 2026	96.34	110.12	92.65	103.10	1.16M
Apr 27, 2026	81.07	101.81	73.40	100.10	3.35M
Apr 23, 2026	71.05	73.55	68.21	69.25	236.22K
Apr 22, 2026	75.05	77.15	67.67	70.31	370K
Apr 21, 2026	74.54	74.97	72.44	73.35	161.8K
Apr 20, 2026	75.91	75.91	71.33	73.97	257.83K
Apr 17, 2026	75.00	77.31	74.55	76.29	261.1K
Apr 16, 2026	80.90	80.90	72.48	74.12	519.39K
Apr 14, 2026	72.00	75.95	69.47	74.99	476.6K
Apr 13, 2026	69.55	72.47	68.30	71.36	656.73K
Apr 10, 2026	60.06	69.57	59.24	68.80	631.45K

Contact Details

New Haven, CT 06513

United States

https://www.veradermics.com 228 372 3376

About Company

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.

Stock Peers

AMAM

0.02+0.07%

Ambrx Biopharma Inc.$28.00 RCUS

0.04+0.16%

Arcus Biosciences, Inc.$24.90 ANRO

0.1+0.41%

Alto Neuroscience, Inc.$24.63 EVMN

-0.52-2.24%

Evommune, Inc.$22.69 BHVN

0.12+1.32%

Biohaven Ltd.$9.20 DNA

-0.33-3.81%

Ginkgo Bioworks Holdings, Inc.$8.34 BTX

-0.09-1.07%

BlackRock Technology and Private Equity Term Trust$8.29 NUVB

0.08+1.68%

Nuvation Bio Inc.$4.84 ADCT

-0.05-1.44%

ADC Therapeutics S.A.$3.43 ANVS

-0.115-4.80%

Annovis Bio, Inc.$2.28

Company Overview

Veradermics, Incorporated (NYSE:MANE) closed at $107.88 USD, gaining $3.98 (3.83%) from the previous close of $103.90. The stock is currently mid-range between its 52-week high and low $32.00 and $117.71. With a market capitalization of about $4.44 billion, Veradermics, Incorporated is classified as a mid-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 529.15 thousand shares, volume is running light vs its 52-week average. Headquartered in New Haven, CT, Veradermics, Incorporated operates in the Healthcare sector and the Biotechnology industry. Led by CEO Reid Waldman, the company employs approximately 21 people and listed since February 04, 2026. Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -0.06%, SMA50 -0.06%, SMA200 -0.06%). The stock’s 14-day RSI is 59.28 (neutral), while the ATR of 4.21 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.78% below its high and over 34.09% above its low. Average 10-day trading volume of 681.80 thousand shares is slightly above the 3-month average of 529.63 thousand, indicating heightened recent market interest.

Valuation Metrics

Veradermics, Incorporated trades at a P/E ratio of -789.74, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 382.67 reflecting a rich premium to book value. The P/FCF stands at -180.64, also below market averages. Compared to sector medians, Veradermics, Incorporated P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Veradermics, Incorporated last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $90.00 to $75.00. The high target offers -13.38% upside. The low target suggests -27.82% downside. The mean target is $81.25. This offers -21.8% upside. Veradermics, Incorporated earnings surprise history is a mixed track record. The quarter that ended March 30, 2026, missed forecasts by -41.47%. The prior quarter beat by -10.31%. Over the last six quarters, Apple has recorded several small beats. These include -10.31% in February 25, 2026.

Financial & Profitability Overview

Over the trailing twelve months, Veradermics has not generated any revenue.
On valuation metrics, Veradermics trades at a P/E of -789.74, P/S of 0.00 and P/B of 382.67. The current ratio is 11.77 and quick ratio is 11.77.

Price Forecast & Outlook

Our AI price prediction model suggests that Veradermics, Incorporated stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 24.23%, with price expected at $129.07 by May 26, 2026, within a range of $121.00 to $136.81 3-Month Outlook: Projected rise of 6.45%, reaching $110.60 by August 10, 2026, with a range of $110.06 to $111.12. 1-Year Outlook: Projected gain of 396.33%, with price at $515.69 by May 12, 2027, within a range of $514.74 to $516.65.

Key Takeaways

currently trading near 52-week highs band. Valuation shows Veradermics, Incorporated trading at a premium to the broader market with a P/E of -789.74. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $81.25, suggesting -21.8% downside. Our AI forecast model points to short-term strength (24.23% over two weeks), a medium-term rise (6.45% over three months), and a longer-term gain (396.33% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Veradermics, Incorporated (MANE) stock price?

Veradermics, Incorporated (NYSE: MANE) stock price is $107.88 in the last trading session. During the trading session, MANE stock reached the peak price of $110.13 while $102.70 was the lowest point it dropped to. The percentage change in MANE stock occurred in the recent session was 3.83% while the dollar amount for the price change in MANE stock was $3.98.

MANE's industry and sector of operation?

The NYSE listed MANE is part of Biotechnology industry that operates in the broader Healthcare sector. Veradermics, Incorporated designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MANE?

No Data

How MANE did perform over past 52-week?

MANE's closing price is 224.69% higher than its 52-week low of $32.00 where as its distance from 52-week high of $117.71 is -11.73%.

How many employees does MANE have?

Number of MANE employees currently stands at 0.

Link for MANE official website?

Official Website of MANE is: https://www.veradermics.com

How do I contact MANE?

MANE could be contacted at phone 228 372 3376 and can also be accessed through its website. MANE operates from 470 James Street, New Haven, CT 06513, United States.

How many shares of MANE are traded daily?

MANE stock volume for the day was 193.49K shares. The average number of MANE shares traded daily for last 3 months was 529.15K.

What is the market cap of MANE currently?

The market value of MANE currently stands at $4.44B with its latest stock price at $107.88 and 41.18M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	0
Sales or Revenue	N/A
5Y Sales Change%	N/A
Fiscal Year Ends	N/A
Sector	Healthcare
Industry	Biotechnology

MANE Company Profile and Key Details

Veradermics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Earnings & Analyst Outlook

Price Forecast & Outlook

Key Takeaways

Dividend & Fair Value

Company Overview

Valuation Metrics